Phenylketonuria and Newborn Screening

• Primary enzymatic defect and phenylalanine accumulation: PAH catalyzes the hydroxylation of phenylalanine to tyrosine via the reaction: phenylalanine + BH₄ + O₂ → tyrosine + dihydrofolate. Loss-of-function mutations in the PAH gene (located on chromosome 12q23.2) result in absent or severely reduced enzyme activity. More than 1,000 mutations have been described, ranging from nonsense mutations causing complete enzyme deficiency to missense mutations causing partial enzyme activity. The consequence is accumulation of phenylalanine to levels typically >20 mg/dL (normal <2 mg/dL), which is the hallmark biochemical finding. The severity of hyperphenylalaninemia correlates with residual enzyme activity: classical PKU involves <1% enzyme activity with phenylalanine >20 mg/dL; mild PKU has 1–3% activity with levels 15–20 mg/dL; and mild hyperphenylalaninemia shows >3% activity with levels 2–15 mg/dL.

• Neurotoxic effects of phenylalanine and metabolite accumulation: Elevated phenylalanine exerts multiple neurotoxic mechanisms. First, competitive inhibition at the large neutral amino acid transporter 1 (LAT1) in the blood-brain barrier prevents transport of other large neutral amino acids including tyrosine, tryptophan, and branched-chain amino acids, which are essential for neurotransmitter and myelin synthesis. This creates functional deficiencies of these amino acids in the CNS despite adequate serum levels. Second, phenylalanine and its metabolites (particularly phenylpyruvate and phenyllactate) accumulate in CSF and brain tissue. Phenylpyruvate, produced through transamination of excess phenylalanine by aminotransferases, is neurotoxic and imparts the characteristic "musty" or "mousy" odor to urine and sweat through volatile metabolite production. Third, elevated phenylalanine inhibits tyrosine synthesis and metabolism, creating secondary tyrosine deficiency despite normal dietary intake. Tyrosine is conditionally essential during periods of rapid brain growth (infancy and early childhood) and is required for synthesis of dopamine, norepinephrine, and epinephrine.

• Disruption of myelin synthesis and white matter development: The combined effect of reduced tyrosine availability and elevated phenylalanine is impaired synthesis of myelin and catecholamine neurotransmitters. Tyrosine is essential for synthesis of DOPA, dopamine, and norepinephrine, which regulate cognitive development, mood, and motor function. Additionally, phenylalanine accumulation interferes with the pentose phosphate pathway and one-carbon metabolism, reducing availability of nucleotides and methylating agents needed for myelin protein synthesis and myelination. Neuroimaging in untreated PKU reveals widespread demyelination and reduced white matter volume, particularly in the corpus callosum, internal capsule, and periventricular regions. This explains the timing of neurological injury—maximal white matter growth occurs between birth and 3 years of age, explaining why permanent intellectual disability develops if treatment is delayed beyond the critical window.

• Secondary deficiencies and systemic effects: Beyond neurotoxicity, tyrosine deficiency in PKU results in reduced melanin synthesis, manifesting as light skin and fair hair (the typical PKU phenotype). Elevated phenylalanine also produces secondary hyperprolactinemia through mechanisms not fully understood, potentially contributing to growth abnormalities. Phenylalanine inhibits branched-chain amino acid absorption in the intestine, leading to secondary deficiencies of leucine, isoleucine, and valine with long-term protein restriction. Chronic dietary protein restriction used in PKU management can lead to deficiencies of other essential amino acids, zinc, and micronutrients if not carefully monitored.

• **Mutations in the PAH gene (classical and variant PKU): Over 1,000 different mutations cause PKU, classified by functional consequences. Nonsense and frameshift mutations typically produce no functional protein and cause classical PKU with complete enzyme deficiency and phenylalanine levels >20 mg/dL. Missense mutations** produce partially functional protein and result in mild or variant PKU with intermediate phenotypes (phenylalanine levels 2–15 mg/dL). The PAH gene demonstrates significant allelic heterogeneity—different populations carry distinct mutation patterns (e.g., certain mutations more common in Celtic populations, others in Asian populations). Geographic ancestry and consanguinity are important risk factors; the disease is 10–20 times more common in populations with high consanguinity rates (Middle East, North Africa) compared to outbred populations.

• Defects in biopterin cofactor synthesis and metabolism (BH₄-responsive PKU and atypical hyperphenylalaninemia): In approximately 2–5% of cases with elevated phenylalanine, the primary defect is not in PAH itself but in the synthesis or recycling of the essential tetrahydrofolate (BH₄) cofactor. This occurs through mutations in genes encoding dihydrofolate reductase (DHFR), GTP cyclohydrolase I (GTPCH), pyruvoyl-tetrahydropterin synthase (PTPS), or sepiapterin reductase (SR). These conditions present with hyperphenylalaninemia due to PAH dysfunction secondary to BH₄ deficiency, NOT primary PAH mutations. Critically, BH₄ deficiency disorders present with additional symptoms beyond PKU-type intellectual disability, including progressive neurodegeneration, seizures, dystonia, and movement disorders (particularly in GTPCH and PTPS deficiency). These patients may show initial responsiveness to BH₄ supplementation if diagnosed early, distinguishing them from classical PAH deficiency.

• Genetic modifiers and penetrance factors: Several genetic and epigenetic factors modulate PKU severity. Synonymous and regulatory mutations in PAH that reduce gene expression without changing the protein sequence can cause mild hyperphenylalaninemia. Genetic background (nuclear genetic modifiers) and environmental factors (dietary protein intake, intercurrent illness) influence baseline phenylalanine levels and thus clinical severity. Patients with identical PAH genotypes may have variable phenotypes based on these modifying factors.

• Classic neurological manifestations in untreated or late-diagnosed PKU: In the absence of early dietary intervention, intellectual disability develops insidiously over the first months of life. Affected infants appear normal at birth with normal physical examination; the first sign is often poor feeding or irritability at 3–6 weeks of age. Progressive developmental delay becomes apparent by 3–6 months with loss of developmental milestones, hypotonia progressing to hypertonia, and eventual severe intellectual disability (IQ typically <30 if untreated). Seizures develop in approximately 75% of untreated cases, typically starting between 6–12 months and often progressing to infantile spasms (flexor or extensor). The characteristic "musty" or "mousy" odor of urine and sweat, caused by volatile phenylketone metabolites (phenylacetate, phenylacetyl-CoA), emerges by 2–3 weeks of age and is highly specific for PKU but usually subtle. Some parents describe it as similar to wet dog or musty basement.

• Physical appearance and skin manifestations: Due to secondary tyrosine deficiency reducing melanin synthesis, classical PKU patients characteristically have fair skin, blonde hair, and blue eyes, contrasting with family members of darker phenotype. This description of a "fair-haired child with developmental delay and seizures in a brown-skinned family" is a classic board presentation. Some infants develop a diffuse eczematous rash resembling atopic dermatitis, thought to relate to tyrosine deficiency and altered collagen synthesis. Affected children often have a characteristic pointed facial appearance with increased nasal ridge prominence.

• Behavioral and psychiatric features: Beyond intellectual disability, untreated PKU manifestations include behavioral abnormalities, anxiety, hyperactivity, and autism spectrum features. The mechanism relates to deficiencies of dopamine and serotonin, whose precursors (tyrosine and tryptophan) are depleted due to LAT1 competitive inhibition.

• Motor findings and hypertonia: Progressive hypertonia (spasticity) affecting lower extremities more than upper extremities is typical, along with tremor, coordination difficulties, and gait abnormalities. Brisk reflexes and extensor plantar responses (Babinski sign) are common. These correlate with white matter demyelination on neuroimaging.

• Variant presentations—mild PKU and maternal PKU: Patients with mild PKU (phenylalanine 15–20 mg/dL) or mild hyperphenylalaninemia (phenylalanine 2–15 mg/dL) detected through newborn screening and treated early typically develop normally or near-normally, highlighting the critical importance of early detection. However, maternal PKU syndrome represents a distinct clinical entity: women with PKU who are pregnant (especially if poorly controlled on diet) expose the fetus to high intrauterine phenylalanine levels. Even though the fetus is typically heterozygous (carrier) and has normal enzyme function, transplacental passage of maternal phenylalanine causes congenital heart defects, microcephaly, intrauterine growth restriction, and intellectual disability in the offspring. This is NOT genetic PKU in the fetus but rather in utero toxicity, emphasizing that women of childbearing age with PKU must maintain strict dietary control.

• Atypical presentations—BH₄-responsive PKU and biopterin deficiency syndromes: Patients with defects in BH₄ synthesis present with hyperphenylalaninemia plus progressive neurodegeneration, movement disorders, seizures, and dystonia that progress despite dietary phenylalanine restriction. Dyskinesia, dystonia, and progressive myoclonic seizures are red flags distinguishing these conditions from classical PAH-deficient PKU.

• Newborn screening—the gold standard for early detection: Elevated blood phenylalanine on tandem mass spectrometry (MS/MS) of dried blood spots (Guthrie cards) is the primary screening test performed at 24–48 hours of life (after adequate protein feeding). Normal phenylalanine is <2 mg/dL (120 μmol/L); screening cutoffs are typically >7–8 mg/dL (425–480 μmol/L) depending on the program, though lower cutoffs (<6 mg/dL) are increasingly used to identify milder cases. Sensitivity approaches 100% when specimens are properly collected after at least 12 hours of feeding. The advantage of MS/MS is simultaneous measurement of leucine/phenylalanine ratio: a low ratio (typically <0.6 in PKU) helps distinguish PKU from other causes of elevated phenylalanine (such as liver disease or transient elevations in premature infants). Second-tier testing on the same spot includes measurement of phenylalanine/tyrosine ratio; PKU shows elevated phenylalanine with low tyrosine levels, while secondary causes show proportionate elevation of both amino acids.

• Confirmatory testing and classification: Infants with positive screening require confirmatory testing within 1–2 weeks. Plasma amino acid analysis by ion-exchange chromatography is performed on a venous blood sample, confirming elevated phenylalanine (>20 mg/dL is classical PKU, 15–20 mg/dL is mild PKU, 2–15 mg/dL is mild hyperphenylalaninemia) and showing low or low-normal tyrosine. Urine organic acid analysis can detect elevated phenylpyruvate and phenyllactate, though this is less commonly used for diagnosis. The phenylalanine/tyrosine ratio in plasma is typically >3:1 in PKU, whereas normal infants have a ratio <1:1.

• BH₄ loading test (critical to identify biopterin-responsive forms): In infants with confirmed hyperphenylalaninemia, a BH₄ loading test should be performed (oral BH₄ 20 mg/kg in a single dose with phenylalanine measurement 4–8 hours later). A decrease in phenylalanine ≥30% indicates BH₄-responsive PKU (usually due to PAH mutations with missense changes affecting cofactor binding) or biopterin synthesis defects. Non-responsive cases indicate classical PAH-deficient PKU. This distinction is critical because responsive cases may benefit from BH₄ supplementation, allowing higher natural protein intake. Additionally, plasma biopterin, neopterin, and primapterin levels should be measured in all positive PKU cases to exclude biopterin synthesis defects, which require different management including serotonin/dopamine replacement in addition to BH₄.

• **Genetic testing and PAH genotyping: DNA sequencing of the PAH gene** confirms the diagnosis and identifies specific mutations, useful for family counseling and understanding potential phenotype (though genotype-phenotype correlation in PKU is imperfect due to multiple factors affecting expression). Genetic testing is increasingly performed as part of expanded newborn screening programs but is not required for diagnosis of the biochemical condition.

• Neuroimaging findings (supporting diagnosis and assessing damage): Magnetic resonance imaging (MRI) of the brain reveals diffuse white matter abnormalities, reduced myelination, and signal changes in periventricular regions, corpus callosum, and internal capsule in untreated or late-treated PKU. Early-treated PKU shows normal or near-normal white matter. MRI is valuable for assessing extent of irreversible brain injury in late diagnoses but is NOT required for diagnosis.

• Differential diagnosis considerations: Other causes of hyperphenylalaninemia must be distinguished: liver disease (elevated phenylalanine with proportionate elevation of other amino acids, hepatic dysfunction tests abnormal), benign hyperphenylalaninemia (phenylalanine 2–6 mg/dL, stable, requires no treatment), tyrosinemia type III (elevated tyrosine more than phenylalanine), and BH₄ deficiency syndromes (diagnosed by neurotransmitter metabolites in CSF or urine and biopterin/neopterin levels).

• Phenylalanine-restricted diet—first-line and foundational therapy: The cornerstone of PKU management is a medically formulated diet restricting natural protein to maintain phenylalanine at target levels (typically

Complications of untreated or late-treated disease

• Irreversible intellectual disability: sustained hyperphenylalaninemia during the myelination window (birth to ~3 years) produces fixed white-matter injury; signaled by loss of milestones and a widening gap between chronologic and developmental age despite later dietary control.
• Epilepsy, including infantile spasms: cortical hyperexcitability from catecholamine/serotonin precursor depletion and demyelination; hypsarrhythmia on EEG in the infant with regression is the tip-off.
• Untreated BH₄ (tetrahydrobiopterin) synthesis/recycling defects: an emergency. Diet lowers phenylalanine but does nothing for absent central dopamine and serotonin synthesis; ongoing dystonia, oculogyric crises, truncal hypotonia, and temperature instability despite normal blood phenylalanine signal it. Requires pterin/neurotransmitter metabolite evaluation and replacement with levodopa-carbidopa plus 5-hydroxytryptophan; in dihydropteridine reductase (DHPR) deficiency, folinic acid must also be given to prevent CNS folate deficiency. Diet alone is never adequate.
• Maternal PKU (fetal hyperphenylalaninemia) syndrome: phenylalanine crosses the placenta by active transport and concentrates in fetal blood; microcephaly, conotruncal heart defects, and IUGR in a genotypically heterozygous fetus. The ACMG/NIH consensus recommendation is to achieve target phenylalanine before conception, since organogenesis is complete before a first prenatal visit; ACOG addresses this within general preconception counseling.

Complications of therapy

• Over-restriction (phenylalanine deficiency): phenylalanine is an essential amino acid; excessive restriction causes catabolism, anorexia, a desquamating acrodermatitis-like rash, anemia, and growth failure. Falling or undetectable phenylalanine on routine monitoring is the signal.
• Micronutrient and macronutrient deficiency from poor medical-food adherence: vitamin B12 deficiency (macrocytosis, neuropathy), essential fatty acid, iron, zinc, and selenium deficiency, and low bone mineral density. Medical food — not natural protein — supplies these.
• Pegvaliase anaphylaxis: an emergency. This PEGylated phenylalanine ammonia-lyase carries a boxed warning and is dispensed under a REMS; patients must carry epinephrine (0.3 mg IM for adults).
• Catabolic intercurrent illness: fever or vomiting mobilizes endogenous protein and drives phenylalanine sharply upward; treat with high-energy intake and increased phenylalanine-free formula.
• Loss to follow-up in adolescence/adulthood: executive dysfunction, anxiety, and depression with reversible white-matter changes on MRI; ACMG recommends lifelong treatment and monitoring.

• The buzzword triad: musty/mousy odor of urine and sweat, fair skin and hair with blue eyes, and eczema in an infant with developmental regression. Odor comes from phenylketones (phenylacetate); the hypopigmentation comes from tyrosine (melanin precursor) deficiency, not from a melanocyte defect.
• Single best next step after a positive newborn screen: quantitative plasma amino acids (phenylalanine and tyrosine) to confirm, plus pterin analysis and dihydropteridine reductase activity to exclude BH₄ (tetrahydrobiopterin — not tetrahydrofolate) defects — and start dietary restriction immediately rather than waiting for results. Delay, not diagnostic error, is what causes brain injury.
• Tyrosine becomes conditionally essential; phenylalanine remains essential. Boards test both directions: supplement tyrosine, but never eliminate phenylalanine entirely.
• The association examiners love: maternal PKU. A mother with PKU off diet produces a heterozygous, biochemically normal infant with microcephaly, congenital heart disease, and IUGR. The damage is in utero toxicity, not the child's genotype, and newborn screening on that infant will be normal.
• Aspartame is contraindicated — it is a dipeptide of aspartate and phenylalanine, which is why diet sodas carry a phenylketonurics warning.
• Screening timing matters: the dried blood spot is collected at 24–48 hours of age, with a repeat specimen if it was obtained before 24 hours or before the infant received enteral protein. Testing before adequate protein exposure and recent red-cell transfusion can produce false negatives; TPN/parenteral amino acids more often cause false-positive phenylalanine elevations requiring a repeat specimen. PKU is on the Recommended Uniform Screening Panel (HRSA/ACHDNC) and is screened in all US states.
• Common distractor 1: "stop the diet after childhood." ACMG recommends lifelong phenylalanine control; adults off diet develop executive dysfunction and mood symptoms.
• Common distractor 2: "breastfeeding is contraindicated." Breast milk is comparatively low in phenylalanine and is combined with phenylalanine-free medical formula under metabolic dietitian supervision.
• Do not confuse with alkaptonuria (homogentisate oxidase deficiency, urine darkens on standing, ochronosis) or homocystinuria (marfanoid habitus, downward lens subluxation, thrombosis).